Viusid in Adults With Acute Fever of Viral Etiology

Effect of VIUSID Administration on Adults With Acute Fever of Viral Etiology

The purpose of the study is to assess the safety and effect of Viusid (bags of 4 grams) administration in the treatment of acute fever of viral etiology as diagnosed by clinical, hematologic and serologic parameters. The duration of this open and randomized phase 2 clinical trial will be 6 days. The estimated number of persons with acute fever of viral etiology to be recruited and randomized for the study is 200. The primary outcome measure: platelet, leukocyte and granulocyte count will be assessed at the beginning and the end of the study.

Inclusion Criteria:

• Acute fever of viral etiology with less than 72 hours of progression
• Signed informed consent.

Exclusion Criteria:

• Patients under treatment with other antioxidants.
• Inability to swallow the content of Viusid bags